Analysts expect that Sanofi SA (NYSE:SNY) will report earnings of $0.98 per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sanofi’s earnings. The lowest EPS estimate is $0.95 and the highest is $1.02. Sanofi posted earnings of $1.00 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 2%. The company is expected to issue its next earnings report before the market opens on Wednesday, October 31st.

On average, analysts expect that Sanofi will report full-year earnings of $3.14 per share for the current year, with EPS estimates ranging from $3.13 to $3.15. For the next fiscal year, analysts anticipate that the business will post earnings of $3.28 per share, with EPS estimates ranging from $3.20 to $3.34. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover Sanofi.

Sanofi (NYSE:SNY) last posted its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.72 by $0.02. The company had revenue of $8.18 billion during the quarter, compared to analyst estimates of $8.27 billion. Sanofi had a net margin of 10.29% and a return on equity of 23.77%. Sanofi’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.35 earnings per share.

Several research analysts have commented on the stock. Zacks Investment Research raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. Guggenheim assumed coverage on shares of Sanofi in a research note on Monday, October 8th. They set a “neutral” rating for the company. BNP Paribas raised shares of Sanofi from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 1st. Deutsche Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, August 1st. Finally, Argus lifted their price objective on shares of Sanofi from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, August 24th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $49.00.

NYSE SNY traded down $0.79 on Friday, hitting $42.89. 1,909,357 shares of the stock were exchanged, compared to its average volume of 1,896,109. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $112.04 billion, a price-to-earnings ratio of 13.70, a PEG ratio of 2.40 and a beta of 0.82. Sanofi has a 52-week low of $37.43 and a 52-week high of $50.04.

In other news, major shareholder Sanofi sold 104,552 shares of Sanofi stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.00% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in SNY. Private Capital Group LLC raised its holdings in shares of Sanofi by 271.3% in the first quarter. Private Capital Group LLC now owns 2,577 shares of the company’s stock valued at $103,000 after acquiring an additional 1,883 shares in the last quarter. IHT Wealth Management LLC raised its holdings in shares of Sanofi by 246.6% in the first quarter. IHT Wealth Management LLC now owns 4,239 shares of the company’s stock valued at $167,000 after acquiring an additional 3,016 shares in the last quarter. Squar Milner Financial Services LLC bought a new stake in shares of Sanofi in the second quarter valued at about $169,000. New England Research & Management Inc. bought a new stake in shares of Sanofi in the third quarter valued at about $205,000. Finally, Natixis bought a new stake in shares of Sanofi in the second quarter valued at about $213,000. Institutional investors and hedge funds own 7.54% of the company’s stock.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Sanofi (SNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.